

Daniel J. Haraf, M.D.

The University of Chicago
Department of Radiation and Cellular Oncology
5758 South Maryland, MC 9006
Chicago, IL 60637
Office: 773-702-5976
Fax: 773-704-7233
Email: धारaf@radonc.uchicago.edu
Web page: <http://www.uchospitals.edu/physicians/daniel-haraf.html>

ACADEMIC APPOINTMENTS

1988-1991 Instructor, Michael Reese Hospital/University of Chicago Center for Radiation Therapy, Department of Radiation and Cellular Oncology.
1991-2000 Assistant Professor, Michael Reese Hospital, Department of Radiation and Cellular Oncology.
1991-1996 Assistant Professor, University of Chicago, Department of Radiation and Cellular Oncology.
1991- Medical Director, University of Chicago Division, Department of Radiation and Cellular Oncology.
1997-2002 Associate Professor, University of Chicago, Department of Radiation and Cellular Oncology
2002- Professor, University of Chicago, Department of Radiation and Cellular Oncology

ACADEMIC TRAINING

1972-1976 B.S. Northern Illinois University, DeKalb, IL
1976-1978 M.S. University of Health Sciences/The Chicago Medical School, Chicago, IL
1978-1982 M.D. University of Health Sciences/The Chicago Medical School, Chicago, IL
1982-1983 Intern, Internal Medicine, Michael Reese Hospital and Medical Center
1983-1985 Resident, Internal Medicine, Michael Reese Hospital and Medical Center
1985-1988 Resident, Radiation Oncology, Michael Reese/University of Chicago

BOARD CERTIFICATION AND LICENSURE

1985 American Board of Internal Medicine
1990 American Board of Radiology

SCHOLARSHIP

- (a) *Peer-reviewed publications in the primary literature, exclusive of abstracts:*
1. Haraf DJ, Booden T, Albach RA: Comparison of several procedures for isolation of nuclei from *E. histolytica*. *J Protozoology* 25:16-17, 1978.
 2. Weichselbaum RR, Beckett MA, Simon MA, McCauley C, Haraf D, Awan A, Samuels B, Nachman J, Dritschillo A: In vitro radiobiological parameters of human sarcoma cell lines. *Int J Radiat Oncol Biol Phys.* 15:937-942, 1988.
<http://www.sciencedirect.com/science/article/pii/0360301688901290>
 3. Kuchnir FT, Heffron J, Myrianthopolus LC, Haraf DJ: Beam's-eye-view aided treatment planning for a nasopharyngeal lesion. *Med Dosim.* 14:231-235, 1989. <http://www.ncbi.nlm.nih.gov/pubmed/2604859>
 4. Rader JS, Haraf DJ, Halpern HJ, Rotmensch J, Spelbring DR, Sutton H, Javaheri G, Herbst AL, Weichselbaum RR: Radiation therapy in the treatment of

- cervical cancer: The University of Chicago/Michael Reese Hospital Experience. *J Surg Oncol.* 44:157-165, 1990.
<http://www.ncbi.nlm.nih.gov/pubmed/2370799>
5. Jaffe DR, Haraf D, Schwartz J, Weichselbaum RR, Diamond AM: Radioresistant derivatives of an x-ray sensitive CHO cell line exhibit distinct patterns of sensitivity to DNA-damaging agents. *Carcinogenesis* 11:1265-1269, 1990. <http://carcin.oxfordjournals.org/content/11/8/1265.long>
 6. Roeske JC, Chen GTY, Atcher RW, Pelizzari CA, Rotmensch J, Haraf D, Montag A, Weichselbaum RR: Modeling of dose to tumor and normal tissue from intraperitoneal radioimmunotherapy with alpha and beta emitters. *Int J Radiat Oncol Biol Phys.* 19:1539-1548, 1990.
<http://www.sciencedirect.com/science/article/pii/036030169090370Y>
 7. Haraf DJ, Drucker DR, Weichselbaum RR, Diamond AM: Radioresistant derivatives of radiosensitive CHO cells obtained following treatment with 5-azacytidine retain their sensitivity to cisplatin. *Radiat Res.* 127:226-229, 1991.
<http://www.ncbi.nlm.nih.gov/pubmed/1719578>
 8. Halpern HJ, Jaffe DR, Nguyen T, Haraf DJ, Spencer DP, Bowman MK, Weichselbaum RR, Diamond AM: Measurement of bioreduction rates of cells with distinct responses to ionizing radiation and cisplatin. *Biochim Biophys Acta.* 1093:121-124, 1991.
<http://www.sciencedirect.com/science/article/pii/016748899190112B>
 9. Haraf DJ, Vokes EE, Panje WR, Weichselbaum RR: Survival and analysis of failure following hydroxyurea, 5-fluorouracil and concomitant radiation therapy in poor prognosis head and neck cancer. *Am J Clin Oncol.* 14:419-426, 1991.
<http://www.ncbi.nlm.nih.gov/pubmed/1719793>
 10. Vokes EE, Moormeier JA, Ratain MJ, Egorin MJ, Haraf DJ, Mick R, Weichselbaum RR: 5-fluorouracil, leucovorin, hydroxyurea and escalating doses of continuous-infusion cisplatin with concomitant radiotherapy: a clinical and pharmacologic study. *Cancer Chemother Pharmacol.* 29:178-184, 1992.
<http://www.ncbi.nlm.nih.gov/pubmed/1733549>
 11. Vokes EE, Weichselbaum RR, Mick R, McEvilly JM, Haraf DJ, Panje WR: Favorable long-term survival following induction chemotherapy with PFL and concomitant chemoradiotherapy for locally advanced head and neck cancer. *J Natl Cancer Inst.* 84:877-882, 1992.
<http://jnci.oxfordjournals.org/content/84/11/877.long>
 12. Haraf DJ, Vokes EE, Weichselbaum RR, Panje WR: Concomitant chemoradiotherapy with cisplatin, 5-fluorouracil and hydroxyurea in poor prognosis head and neck cancer. *Laryngoscope.* 102:630-636, 1992.
<http://onlinelibrary.wiley.com/doi/10.1288/00005537-199206000-00007/epdf>
 13. Meechan PJ, Haraf DJ, Diamond AM, Grdina DJ: Reversion of radiosensitivity in azacytidine-treated xrs-5 cells does not result in full radioprotection by WR1065. *Int J Radiat Oncol Biol Phys.* 23:999-1002, 1992.
<http://www.sciencedirect.com/science/article/pii/036030169290905W>
 14. Brachman DG, Graves D, Vokes E, Beckett M, Haraf D, Montag A, Dunphy E, Mick R, Yandell D, Weichselbaum RR: Occurrence of p53 gene deletions and human papilloma virus infection in human head and neck. *Cancer Res.* 52:4832-4836, 1992.
<http://cancerres.aacrjournals.org/content/52/17/4832.long>
 15. Vokes EE, Haraf DJ, McEvilly JM, Mick R, Kozloff MF, Goldman MD, Moran WJ, Clendennin N, Collier N, Weichselbaum RR, Panje WR: Neoadjuvant

- PFL augmented by methotrexate and piritrexim followed by a concomitant chemotherapy for advanced head and neck cancer: A feasible and active approach. *Ann Oncol.* 3:79-81, 1992.
<http://annonc.oxfordjournals.org/content/3/1/79.long>
16. Haraf DJ, Kuchnir FT, Watson-Bullock S, Brachman D, Dougherty M, Rubin S, Sutton H: A dosimetric study comparing three-, four- and six-field plans for treatment of carcinoma of the prostate. *Med Dosimetry.* 17:191-198, 1992. <http://www.ncbi.nlm.nih.gov/pubmed/1485906>
 17. Vokes EE, Ratain MJ, Mick R, McEvilly JM, Haraf DJ, Kozloff M, Hamasaki V, Weichselbaum RR, Panje WR, Berezin F: Cisplatin, fluorouracil, and leucovorin augmented by interferon alpha-2b in head and neck cancer: A clinical and pharmacologic analysis. *J Clin Oncol.* 11:360-368, 1993. <http://jco.ascopubs.org/lookup/pmid?view=long&pmid=8426214>
 18. Rosen GM, Vokes EE, Scher N, Haraf DJ, Weichselbaum RR, Panje WR: Locoregionally advanced paranasal sinus carcinoma. Favorable survival with multimodality therapy. *Arch Otolaryngol Head Neck Surg.* 119:743-746, 1993. <http://archotol.jamanetwork.com/article.aspx?articleid=621701>
 19. Brachman DG, Beckett M, Graves D, Haraf D, Vokes E, Weichselbaum RR: p53 mutation does not correlate with radiosensitivity in 24 head and neck cancer cell lines. *Cancer Res.* 53:3667-3669, 1993. <http://cancerres.aacrjournals.org/content/53/16/3667.long>
 20. Vokes EE, Haraf DJ, Hoffman PC: Escalating doses of interferon alpha-2A with cisplatin and concomitant radiotherapy: A phase I study. *Cancer Chemother Pharmacol.* 33:203-209, 1993. <http://www.ncbi.nlm.nih.gov/pubmed/8269601>
 21. Ruckstalis DB, Gerber GS, Vogelzang NJ, Haraf DJ, Straus FH III, Chodak GW: Laparoscopic pelvic lymph node dissection: A review of 103 consecutive cases. *J Urol.* 151:670-674, 1994. <http://www.ncbi.nlm.nih.gov/pubmed/7508525>
 22. Wong WW, Mick R, Haraf DJ, Weichselbaum RR, Vokes EE: Time-dose relationship for tumor control following alternate week concomitant radiation and chemotherapy of advanced head and neck cancer. *Int J Radiat Oncol Biol Phys.* 29:153-162, 1994. <http://www.sciencedirect.com/science/article/pii/0360301694902380>
 23. Karnell MP, MacCracken E, Moran WJ, Vokes EE, Haraf D, Panje WR: Swallowing function following multispecialty organ preservation treatment of advanced head and neck cancer. *Oncology Reports* 1:597-601, 1994. <http://www.spandidos-publications.com/or/1/3/597>
 24. Vokes EE, Haraf DJ, Hoffman PC, Bitran JD, Ferguson MK, Golomb HM: Concomitant chemoradiotherapy for non-small cell lung cancer. *Lung Cancer* 10:S253-S261, 1994. <http://www.ncbi.nlm.nih.gov/pubmed/8087518>
 25. Vokes EE, Haraf DJ, Mick R, McEvilly JM, Weichselbaum RR: Intensified concomitant chemoradiotherapy with and without filgrastim for poor prognosis head and neck cancer. *J Clin Oncol.* 12:2351-2359, 1994. <http://jco.ascopubs.org/content/12/11/2351.long>
 26. Meecham PJ, Haraf DJ, Diamond AM, Grdina DJ: Varying levels of radioprotection from the effects of JANUS neutrons in repair-deficient xrs-5 hamster cells treated with azacytidine. *Rad Research* 140:437-440, 1994. <http://www.ncbi.nlm.nih.gov/pubmed/7526412>
 27. Vijayakumar S, Karrison T, Quadri SF, Chan SK, Haraf D, Pandya K, Houghton A, Rubin S, Kalokhe U, Halpern H, Muller-Runkel R, Sutton H, Awan A,

- Weichselbaum R: Localized prostate cancer: Use of serial prostate specific antigen measurements during radiation therapy - An update. *Onkologie* 17:578-585, 1994.
<http://www.karger.com/Article/Abstract/218481>
28. Gradishar WJ, Haraf DJ, Hoffman PC, Rademaker AW, Ferguson MK, Golomb H, Bitran JD, Vokes EE: A phase II trial of neoadjuvant chemoradiotherapy for the treatment of locally advanced non-small cell lung cancer. *Oncology Reports* 1:957-962, 1994.
<http://www.spandidos-publications.com/or/1/5/957>
 29. Vokes EE, Haraf DJ, Drinkard LC, Hoffman PC, Ferguson MK, Vogelzang NJ, Watson S, Lane NJ, Golomb HM: A phase I trial of concomitant chemoradiotherapy with cisplatin dose intensification and granulocyte-colony stimulating factor support for advanced malignancies of the chest. *Cancer Chemother Pharmacol.* 35:304-312, 1995.
<http://www.ncbi.nlm.nih.gov/pubmed/7530173>
 30. Ferguson MK, Reeder LB, Hoffman PC, Haraf DJ, Drinkard LC, Vokes EE: Intensive multimodality therapy for carcinoma of the esophagus and gastroesophageal junction. *Ann Surg Oncol.* 2:101-106, 1995.
<http://www.ncbi.nlm.nih.gov/pubmed/7728562>
 31. Panje WR, Namon AJ, Vokes E, Haraf DJ, Weichselbaum RR: Surgical management of the head and neck cancer patient following concomitant multimodality therapy. *Laryngoscope* 105:97-101, 1995.
<http://onlinelibrary.wiley.com/doi/10.1288/00005537-199501000-00021/epdf>
 32. Vokes EE, Kies M, Haraf DJ, Mick R, Moran WJ, Kozloff M, Mittal B, Pelzer H, Wenig B, Panje W, Weichselbaum RR: Induction chemotherapy followed by concomitant chemoradiotherapy for advanced head and neck cancer: Impact on the natural history of the disease. *J Clin Oncol.* 13:876-883, 1995. <http://jco.ascopubs.org/content/13/4/876.long>
 33. Haraf DJ, Rubin SJ, Sweeney P, Kuchnir FT, Sutton HS, Chodak GW, Farah R, Weichselbaum RR: Photon neutron mixed beam radiotherapy of locally advanced prostate cancer: Results at the University of Chicago. *Int J Radiat Oncol Biol Phys* 33:3-14, 1995.
<http://www.sciencedirect.com/science/article/pii/036030169500181W>
 34. Yong L, Song PY, Li S, Spelbring DR, Vijayakumar S, Haraf DJ, Chen GTY: A method of analyzing rectal surface area irradiated and rectal complications in prostate conformal radiotherapy. *Int J Radiat Oncol Biol Phys* 33:1121-1125, 1995.
<http://www.sciencedirect.com/science/article/pii/0360301695020306>
 35. Pelizzari CA, Grzeszczuk R, Chen GTY, Heimann R, Haraf DJ, Vijayakumar S, Ryan MJ: Volumetric visualization of anatomy for treatment planning. *Int J Radiat Oncol Biol Phys* 34:205-211, 1996.
<http://www.ncbi.nlm.nih.gov/pubmed/12118552>
 36. Roeske JC, Kuchnir FT, Mundt AJ, Haraf DJ: Electron-photon field matching for treatment of paranasal sinus tumors: *Med Dosimetry* 21:31-36, 1996.
<http://www.ncbi.nlm.nih.gov/pubmed/8679069>
 37. Haraf DJ, Nodzinski E, Mick R, Brachman D, Montag A, Graves D, Vokes EE, Weichselbaum RR: HPV and p53 in head and neck cancer: Clinical correlates and survival. *Clin Can Res* 2:755-762, 1996.
<http://clincancerres.aacrjournals.org/content/2/4/755.long>
 38. Vokes EE, Mick R, Kies MS, Dolan E, Malone D, Athansiadis I, Haraf DJ, Kozloff M, Weichselbaum RR, Ratian MJ: Pharmacodynamics of fluorouracil-based induction chemotherapy in advanced head and neck cancer. *J Clin*

- Oncol. 16:1663-1671, 1996.
<http://jco.ascopubs.org/content/14/5/1663.long>
39. List MA, D'Antonio LA, Cella DF, Siston A, Mumby P, Haraf D, Vokes E: The performance status scale for head and neck cancer patients and the functional assessment of cancer therapy-head and neck scale. A study of utility and validity. *Cancer* 77:2294-2301, 1996.
<http://www.ncbi.nlm.nih.gov/pubmed/8635098>
 40. Gerber GS, Bales GT, Gornik HL, Haraf DJ, Chodak GW, Rukstalis DB: Treatment of prostate cancer after laproscopic pelvic lymph node dissection. *Br J Urol.* 77:870-875, 1996. <http://www.ncbi.nlm.nih.gov/pubmed/8705224>
 41. Sweeney PJ, Haraf DJ, Recant W, Kaplan EL, Vokes EE: Anaplastic carcinoma of the thyroid. *Ann Oncol.* 7:739-744, 1996.
<http://annonc.oxfordjournals.org/content/7/7/739.long>
 42. Haraf DJ, Weichselbaum RR, Vokes EE: Reirradiation with concomitant chemotherapy of recurrent unresectable head and neck cancer: A potentially curable disease. *Ann Oncol* 7:913-918, 1996.
<http://annonc.oxfordjournals.org/content/7/9/913.long>
 43. Chen LM, Haraf D, Brachman DG, Vokes EE, Schilsky RL: Concomitant 5-FU, hydroxyurea and cisplatin with external beam radiation therapy for locally advanced pancreatic cancer: A phase II study. *Oncol Reports* 4:877-881, 1997. <http://www.spandidos-publications.com/or/4/5/877>
 44. Toljanic JA, Ali M, Haraf DJ, Vokes EE, Moran WJ, Graham L: Osteoradionecrosis of the jaws as a risk factor in radiotherapy: A report of an eight-year retrospective review. *Oncol Reports* 5:345-349, 1998.
<http://www.spandidos-publications.com/or/5/2/345>
 45. Mauer AM, Masters GA, Haraf DJ, Hoffman PC, Watson SM, Golomb HM, Vokes EE: Phase I study of docetaxel with concomitant thoracic radiation therapy. *J Clin Oncol* 16:159-164, 1998.
<http://jco.ascopubs.org/content/16/1/159.long>
 46. Brockstein B, Haraf DJ, Stenson K, Fasanmade A, Stupp R, Glisson B, Lippman SM, Ratain M, Sulzen L, Klepsch A, Weichselbaum RR, Vokes EE: Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, and hydroxyurea with granulocyte colony-stimulating factor support for patients with poor-prognosis cancer of the head and neck. *J Clin Oncol* 16:735-744, 1998. <http://jco.ascopubs.org/content/16/2/735.long>
 47. Keis MS, Haraf DJ, Athanasiadis I, Kozloff M, Mittal B, Pelzer H, Rademaker AW, Wenig B, Weichselbaum RR, Vokes EE: Induction chemotherapy followed by concurrent chemoradiation for advanced head and neck cancer: Improved disease control and survival. *J Clin Oncol* 16:2715-2721, 1998. <http://jco.ascopubs.org/content/16/8/2715.long>
 48. List MA, Mumby P, Haraf D, Siston A, Mick R, MacCracken E, Vokes E: Performance and quality of life outcome in patients completing concomitant chemoradiotherapy protocols for head and neck cancer. *Qual Life Res* 6:274-284, 1997.
<http://www.ncbi.nlm.nih.gov/pubmed/9226985>
 49. Masters GA, Haraf DJ, Hoffman PC, Drinkard LC, Krauss SA, Ferguson MK, Olak J, Samuels BL, Golomb HM, Vokes EE: Phase I study of vinorelbine, cisplatin, and concomitant thoracic radiation in the treatment of advanced chest malignancies. *J Clin Oncol* 16:2157-2163, 1998.
<http://jco.ascopubs.org/content/16/6/2157.long>
 50. Humerickhouse RA, Dolan ME, Haraf DJ, Brockstein B, Stenson K, Kies M, Sulzen L, Ratain MJ, Vokes EE: Phase I study of eniluracil, a dihydropyrimidine

- dehydrogenase inactivator, and oral 5-fluorouracil with radiation therapy in patients with recurrent or advanced head and neck cancer. *Clin Cancer Res* 1999 Feb;5(2):291-298, 1999.
<http://clincancerres.aacrjournals.org/lookup/pmid?view=long&pmid=10037177>
51. Haraf DJ, Kies M, Rademaker AW, Stenson K, Mittal B, Pelzer H, Wenig B, Witt ME, Sulzen L, Weichselbaum RR, Vokes EE: Radiation therapy with concomitant hydroxyurea and fluorouracil in stage II and III head and neck cancer. *J Clin Oncol* 17:638-644, 1999.
<http://jco.ascopubs.org/content/17/2/638.long>
 52. List MA, Siston A, Haraf D, Schumm P, Kies M, Stenson K, Vokes EE: Quality of life and performance in advanced head and neck cancer patients on concomitant chemoradiotherapy: a prospective examination. *J Clin Oncol* 17:1020-1028,1999. <http://jco.ascopubs.org/content/17/3/1020.long>
 53. Lee JS, Jani AB, Pellizzari CA, Haraf DJ, Vokes EE, Weichselbaum RR, Chen GTY: Volumetric visualization of head and neck CT data for treatment planning. *Int J Radiat Oncol Biol Phys.* 44:693-703, 1999.
<http://www.sciencedirect.com/science/article/pii/S0360301699000425>
 54. Lee MM, Vokes EE, Rosen A, Witt ME, Weichselbaum RR, Haraf DJ: Multimodality therapy in advanced paranasal sinus carcinoma: Superior long-term results. *Cancer J* 5:219-223, 1999.
<http://www.ncbi.nlm.nih.gov/pubmed/10439167>
 55. Johnson LS, Milliken BD, Hadley SW, Pelizzari CA, Haraf DJ, Chen GT: Initial clinical experience with a video-based patient positioning system. *Int J Radiat Oncol Biol Phys* 45:205-213, 1999.
<http://www.sciencedirect.com/science/article/pii/S0360301699001820>
 56. Ferguson MK, Wang J, Hoffman PC, Haraf DJ, Olak J, Masters GA, Vokes EE: Sex-associated differences in survival of patients undergoing resection for lung cancer. *Ann Thorac Surg* 69:249-250, 2000.
<http://www.sciencedirect.com/science/article/pii/S0003497599010784>
 57. List MA, Stracks J, Colangelo L, Butler P, Ganzenko N, Lundy D, Sullivan P, Haraf D, Kies M, Goodwin W, Vokes EE: How do head and neck cancer patients prioritize treatment outcomes before initiating treatment? *J Clin Oncol* 14:877, 2000. <http://jco.ascopubs.org/content/18/4/877.long>
 58. Chen LM, Godinez J, Thisted RA, Woodle ES, Thistlewaite JR, Powers C, Haraf DJ: New scoring system identifies kidney outcome with radiation therapy in acute renal allograft rejection. *Int J Radiat Oncol Biol Phys.* 40:999-1003, 2000.
<http://www.sciencedirect.com/science/article/pii/S0360301699004745>
 59. Stenson KM, MacCracken E, List M, Haraf DJ, Brockstein B, Weichselbaum R, Vokes EE: Swallowing function in patients with head and neck cancer prior to treatment. *Arch Otolaryngol Head Neck Surg.* 126:371-377, 2000. <http://archotol.jamanetwork.com/article.aspx?articleid=404294>
 60. Brockstein B, Haraf DJ, Stenson K, Sulzen L, Witt ME, Weichselbaum RW, Vokes EE: A phase I-II study of concomitant chemoradiotherapy with paclitaxel (one-hour infusion), 5-fluorouracil and hydroxyurea with granulocyte colony stimulating factor support for patients with poor prognosis head and neck cancer. *Ann Oncol* 11:721-728, 2000.
<http://annonc.oxfordjournals.org/content/11/6/721.long>
 61. Stenson KM, Haraf DJ, Pelzer H, Recant W, Kies MS, Weichselbaum RR, Vokes EE: The role of cervical lymphadenopathy after aggressive concomitant chemoradiotherapy: the feasibility of selective neck dissection. *Arch Otolaryngol Head Neck Surg* 126:950-956, 2000.

- <http://archotol.jamanetwork.com/article.aspx?articleid=405181>
62. Vokes EE, Kies MS, Haraf DJ, Stenson K, List M, Hummerickhouse R, Dolan ME, Pelzer H, Sulzen L, Witt ME, Hsieh YC, Mittal BB, Weichselbaum RR: Concomitant chemoradiotherapy as primary therapy for locoregionally advanced head and neck cancer. *J Clin Oncol* 18:1652-1661, 2000.
<http://jco.ascopubs.org/content/18/8/1652.long>
63. Connell PP, Ignacio L, Haraf D, Awan AM, Halpern H, Abdalla I, Nautiyal J, Jani A, Weichselbaum RR: Equivalent racial outcome after conformal radiotherapy for prostate cancer. *J Clin Oncol* 19:54-61, 2001.
<http://jco.ascopubs.org/content/19/1/54.long>
64. Kies MS, Haraf DJ, Rosen F, Stenson K, List M, Brockstein B, Chung T, Mittal BB, Pelzer H, Portugal L, Rademaker A, Weichselbaum R, Vokes EE: Concomitant infusional paclitaxel and 5-fluorouracil, oral hydroxyurea and hyperfractionated radiation for locally advanced squamous head and neck cancer. *J Clin Oncol* 19:1961-1969, 2001.
<http://jco.ascopubs.org/content/19/7/1961.long>
65. Mantz CA, Vokes EE, Kies M, Mittal B, Witt ME, List MA, Weichselbaum RR, Haraf DJ: Sequential induction chemotherapy and concomitant chemoradiotherapy in the management of locoregionally advanced laryngeal cancer. *Ann Oncol* 12:343-347, 2001.
<http://annonc.oxfordjournals.org/content/12/3/343.long>
66. Mantz CA, Vokes EE, Stenson K, Kies M, Mittal B, Witt ME, List MA, Weichselbaum RR, Haraf DJ: Induction chemotherapy followed by concomitant chemoradiotherapy in the treatment of locoregionally advanced oropharyngeal cancer. *Cancer J* 7:140-148, 2001.
<http://www.ncbi.nlm.nih.gov/pubmed/11324767>
67. George CA, Haraf DJ, Mauer AM, Krauss SA, Hoffman PC, Rudin CM, Szeto L, Vokes EE: A phase I trial of the oral platinum analogue JM216 with concomitant radiotherapy in advanced malignancies of the chest. *Invest New Drugs* 19:303-310, 2001.
<http://www.ncbi.nlm.nih.gov/pubmed/11561689>
68. List MA, Lee Rutherford J, Stracks J, Haraf D, Kies MS, Vokes EE: An exploration of pretreatment coping strategies of patients with carcinoma of the head and neck. *Cancer* 95:98-104, 2002.
<http://onlinelibrary.wiley.com/doi/10.1002/cncr.10653/epdf>
69. Hoffman P, Cohen E, Masters G, Haraf D, Mauer A, Rudin C, Krauss S, Huo D, Vokes E: Carboplatin plus vinorelbine with concomitant radiation therapy in advanced non-small cell lung cancer: a phase I study. *Lung Cancer* 38:65-71, 2002.
<http://www.sciencedirect.com/science/article/pii/S0169500202001447>
70. Vokes EE, Stenson K, Rosen FR, Kies MS, Rademaker AW, Witt ME, Brockstein BE, List MA, Fung BB, Portugal L, Mittal BB, Pelzer H, Weichselbaum RR, Haraf DJ: Weekly Carboplatin and Paclitaxel Followed by Concomitant TFX Chemoradiotherapy: Curative and Organ Preserving Therapy for Advanced Head and Neck Cancer. *J Clin Oncol* 21:320-326, 2003. <http://jco.ascopubs.org/content/21/2/320.long>
71. Oh J, Vokes EE, Witt ME, Mittal B, Pelzer H, Weichselbaum RR, Haraf DJ: Induction chemotherapy followed by concurrent chemoradiation for advanced nasopharyngeal carcinoma. *Ann Oncol* 14:564-569, 2003.
<http://annonc.oxfordjournals.org/lookup/pmid?view=long&pmid=12649102>
72. Rosen F, Haraf DJ, Kies MS, Portugal L, List M, Brockstein B, Chung T, Mittal BB, Stenson K, Pelzer H, Rademaker A, Weichselbaum R, Vokes EE:

Multicenter Randomized Phase II Study of Paclitaxel (1 hour infusion), Fluorouracil, Hydroxyurea and Concomitant Hyperfractionated Radiation with or without Erythropoietin for Advanced Oral, Pharynx and Larynx Cancer. Clin Ca Res 9:1689-1687, 2003.

<http://clincancerres.aacrjournals.org/lookup/pmid?view=long&pmid=12738722>

73. Argiris A, Smith SM, Stenson K, Mittal BB, Pelzer HJ, Kies MS, Haraf DJ, Vokes EE: Concurrent chemoradiotherapy for N2 or N3 squamous cell carcinoma of the head and neck from an occult primary. Ann Oncol 14:1306-1311, 2003. <http://annonc.oxfordjournals.org/content/14/8/1306.long>
74. Lamont EB, Hayreh D, Pickett KE, Dignan JJ, List MA, Stenson KM, Haraf DJ, Brockstein BE, Sellergren SA, Vokes EE: Is patient travel distance associated with survival on phase II clinical trials in oncology? JNCI 95:1370-1375, 2003. <http://jnci.oxfordjournals.org/content/95/18/1370.long>
75. Mittal BB, Pauloski BR, Haraf DJ, Pelzer HJ, Argiris A, Vokes EE, Rademaker A, Logemann JA: Swallowing dysfunction- preventative and rehabilitation strategies in patients with head-and-neck cancers treated with surgery, radiotherapy, and chemotherapy: A critical review. Int J Radiat Oncol Biol Phys 57:1219-1230, 2003. <http://www.sciencedirect.com/science/article/pii/S0360301603014548>
76. Haraf DJ, Rosen F, Stenson K, Argiris A, Mittal BB, Witt ME, Brockstein BE, List MA, Portugal L, Pelzer H, Weichselbaum RR, Vokes EE: Induction chemotherapy followed by concomitant TFHX chemoradiotherapy with reduced dose radiation in advanced head and neck cancer. Clin Ca Res 9:5936-5943, 2003. <http://clincancerres.aacrjournals.org/lookup/pmid?view=long&pmid=14676118>
77. Brockstein B, Mundt A, Haraf DJ, Ferguson M, Montag A: Radiation-induced leiomyosarcoma: does antimetabolite chemotherapy contribute? A report of three cases. Sarcoma 7:167-172, 2003. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2395527/>
78. Argiris A, Brockstein BE, Haraf DJ, Stenson KM, Mittal BB, Kies MS, Rosen FR, Jovanovic B, Vokes EE: Competing causes of death and second primary tumors in patients with locoregionally advanced head and neck cancer treated with chemoradiotherapy. Clin Ca Res 10:1956-1962, 2004. <http://clincancerres.aacrjournals.org/lookup/pmid?view=long&pmid=15041712>
79. Brockstein B, Haraf DJ, Rademaker AW, Kies MS, Stenson KM, Rosen F, Mittal BB, Pelzer H, Fung BB, Witt ME, Wenig B, Portugal L, Weichselbaum RR, Vokes EE: Patterns of failure, prognostic factors, and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy: a 9-year, 337 patient, multi-institutional experience. Ann Oncol 15:1179-1186, 2004. <http://annonc.oxfordjournals.org/content/15/8/1179.long>
80. Argiris A, Stenson KM, Brockstein BE, Mittal BB, Pelzer H, Kies MS, Jayaram P, Portugal L, Wenig BL, Rosen FR, Haraf DJ, Vokes EE: Neck dissection in the combined-modality therapy of patients with locoregionally advanced head and neck cancer. Head Neck 26:447-455, 2004. <http://onlinelibrary.wiley.com/doi/10.1002/hed.10394/abstract>
81. Milano MT, Haraf DJ, Stenson KM, Witt ME, Eng C, Mittal BB, Argiris A, Pelzer H, Kozloff MF, Vokes EE: Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, gemcytabine, and twice-daily radiation in patients with poor-prognosis cancer of the head and neck. Clin Ca Res 10:4922-4932, 2004.

- <http://clincancerres.aacrjournals.org/lookup/pmid?view=long&pmid=15297392>
82. Mehta N, Mauer AM, Hellman S, Haraf DJ, Cohen EE, Vokes EE, Weichselbaum RR. Analysis of further disease progression in metastatic non-small cell lung cancer: Implications for locoregional treatment. *Int J Oncol* 25:1677-1683, 2004.
<http://www.spandidos-publications.com/ijournal/25/6/1677>
83. Chmura SJ, Milano MT, Haraf DJ. Reirradiation of recurrent head and neck cancers with curative intent. *Semin Oncol* 31:816-21, 2004.
<http://www.sciencedirect.com/science/article/pii/S0093775404004002>
84. Milano MT, Vokes EE, Salama JK, Stenson KM, Kao J, Witt ME, Mittal BB, Argiris A, Weichselbaum RR, Haraf DJ. Twice-daily reirradiation for recurrent and second primary head-and-neck cancer with gemcitabine, paclitaxel, and 5-fluorouracil chemotherapy. *Int J Radiat Oncol Biol Phys*. 61(4):1096-106, 2005.
<http://www.sciencedirect.com/science/article/pii/S0360301604022795>
85. Salama JK, Haraf DJ, Stenson K, Milano MT, Witt ME, Vokes EE. Phase I study of concomitant chemoradiotherapy with irinotecan, 5-FU, and hydroxyurea for patients with advanced and/or recurrent head and neck cancer. *Cancer J*. 11(2):140-6, 2005.
<http://www.ncbi.nlm.nih.gov/pubmed/15969989>
86. Salama JK, Vokes EE, Chmura SJ, Milano MT, Kao J, Stenson KM, Witt ME, Haraf DJ. Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinoma. *Int J Radiat Oncol Biol Phys*. 64:382-391, 2006.
<http://www.sciencedirect.com/science/article/pii/S036030160501165X>
87. Logemann JA, Rademaker AW, Pauloski BR, Lazarus CL, Mittal BB, Brockstein B, Maccracken E, Haraf DJ, Vokes EE, Newman LA, Liu D. Site of disease and treatment protocol as correlates of swallowing function in patients with head and neck cancer treated with chemoradiation. *Head Neck*. 28:64-73, 2006.
<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1380204/pdf/nihms7896.pdf>
88. Stenson KM, Huo D, Blair E, Cohen EE, Argiris A, Haraf DJ, Vokes EE. Planned post-chemoradiation neck dissection: significance of radiation dose. *Laryngoscope* 116: 33-36, 2006.
<http://onlinelibrary.wiley.com/doi/10.1097/O1.mlg.0000185846.27617.fe/epdf>
89. Connell PP, Jayathilaka K, Haraf DJ, Weichselbaum RR, Vokes EE, Lingen MW. Pilot study examining tumor expression of RAD51 and clinical outcomes in human head cancers. *Int J Oncol* 28:1113-1119, 2006.
<http://www.spandidos-publications.com/ijournal/28/5/1113>
90. Milano MT, Vokes EE, Kao J, Jackson W, List MA, Stenson KM, Witt ME, Dekker A, MacCracken E, Garofalo MC, Chmura SJ, Weichselbaum RR, Haraf DJ. Intensity-modulated radiation therapy in advanced head and neck patients treated with intensive chemoradiotherapy: preliminary experience and future directions. *Int J Oncol* 28:1141-1151, 2006.
<http://www.spandidos-publications.com/ijournal/28/5/1141>
91. Cohen EE, Haraf DJ, List MA, Kocherginsky M, Mittal BB, Rosen F, Brockstein B, Williams R, Witt ME, Stenson KM, Kies MS, Vokes EE. High Survival and Organ Function Rates After Primary Chemoradiotherapy for Intermediate-Stage Squamous Cell Carcinoma of the Head and Neck Treated in a Multicenter Phase II Trial. *J Clin Oncol* 20;24(21):3438-44, 2006.
<http://jco.ascopubs.org/content/24/21/3438.full.pdf+html>

92. Lazarus C, Logemann JA, Pauloski BR, Rademaker AW, Helenowski IB, Vonesh EF, Maccracken E, Mittal BB, Vokes EE, Haraf DJ. Effects of radiotherapy with or without chemotherapy on tongue strength and swallowing in patients with oral cancer. *Head Neck* 29:632-637, 2007.
<http://onlinelibrary.wiley.com/doi/10.1002/hed.20577/epdf>
93. Seiwert TY, Connell PP, Mauer AM, Hoffman PC, George CM, Szeto L, Salgia R, Posther KE, Nguyen B, Haraf DJ, Vokes EE. A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer. *Clin Cancer Res* 15;13(2 Pt 1):515-22, 2007.
<http://clincancerres.aacrjournals.org/content/13/2/515.long>
94. Cohen EE, Rosine D, Haraf DJ, Loh E, Shen L, Lusinchi A, Vokes EE, Bourhis J. Phase I trial of tirapazamine, cisplatin, and concurrent accelerated boost reirradiation in patients with recurrent head and neck cancer. *Int J Radiat Oncol Biol Phys* 1;67(3):678-84, 2007.
<http://www.sciencedirect.com/science/article/pii/S0360301606033712>
95. Shaikh AY, Haraf DJ, Salama JK, Salgia R, Hoffman PC, Ferguson MK, Connell PP. Chemotherapy and high dose radiotherapy followed by resection for locally advanced nonsmall cell lung cancers. *Am J Clin Oncol* 30(3):258-63, 2007. <http://www.ncbi.nlm.nih.gov/pubmed/17551302>
96. Seiwert TY, Cohen EE, Haraf DJ, Stenson K, Blair EA, Mauer A, Dekker A, Vokes EE. A phase I trial of docetaxel based induction and concomitant chemotherapy in patients with locally advanced head and neck cancer. *Cancer Invest* 25(6):435-44, 2007.
<http://informahealthcare.com/doi/pdf/10.1080/07357900701357993>
97. Langerman A, Maccracken E, Kasza K, Haraf DJ, Vokes EE, Stenson KM. Aspiration in chemoradiated patients with head and neck cancer. *Arch Otolaryngol Head Neck Surg* 133(12):1289-95, 2007.
<http://archotol.jamanetwork.com/article.aspx?articleid=484910>
98. Choong NW, Vokes EE, Haraf DJ, Tothy PK, Ferguson MK, Kasza K, Rudin CM, Hoffman PC, Krauss SA, Szeto L, Mauer AM. Phase I study of induction chemotherapy and concomitant chemoradiotherapy with irinotecan, carboplatin, and paclitaxel for stage III non-small cell lung cancer. *J Thorac Oncol* 3(1):59-67, 2008.
<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3742080/>
99. Seiwert TY, Haraf DJ, Cohen EE, Stenson K, Witt ME, Dekker A, Kocherginsky M, Weichselbaum RR, Chen HX, Vokes EE. Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer. *J Clin Oncol* 1;26(10):1732-41, 2008.
<http://jco.ascopubs.org/content/26/10/1732.full.pdf+html>
100. Knab BR, Salama JK, Solanki A, Stenson KM, Cohen EE, Witt ME, Haraf DJ, Vokes EE. Functional organ preservation with definitive chemoradiotherapy for T4 laryngeal squamous cell carcinoma. *Ann Oncol*. 19(9):1650-4, 2008.
<http://annonc.oxfordjournals.org/content/19/9/1650.long>
101. Salama JK, Stenson KM, Kistner EO, Mittal BB, Argiris A, Witt ME, Rosen F, Brockstein BE, Cohen EE, Haraf DJ, Vokes EE. Induction chemotherapy and concurrent chemoradiotherapy for locoregionally advanced head and neck cancer: a multi-institutional phase II trial investigating three radiotherapy dose levels. *Ann Oncol*. 19(10):1787-94, 2008.
<http://annonc.oxfordjournals.org/content/19/10/1787.long>

102. Cohn AB, Lang PO, Agarwal JP, Peng SL, Alizadeh K, Stenson KM, Haraf DJ, Cohen EE, Vokes EE, Gottlieb LJ. Free-flap reconstruction in the doubly irradiated patient population. *Plast Reconstr Surg.* 122(1):125-32, 2008. <http://www.ncbi.nlm.nih.gov/pubmed/18594395>
103. Salama JK, Chmura SJ, Mehta N, Yenice KM, Stadler WM, Vokes EE, Haraf DJ, Hellman S, Weichselbaum RR. An initial report of a radiation dose-escalation trial in patients with one to five sites of metastatic disease. *Clin Cancer Res.* 15;14(16):5255-9, 2008. <http://clincancerres.aacrjournals.org/content/14/16/5255.long>
104. Choong NW, Mauer AM, Haraf DJ, Lester E, Hoffman PC, Kozloff M, Lin S, Dancey JE, Szeto L, Grushko T, Olopade OI, Salgia R, Vokes EE. Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer. *J Thorac Oncol.* 3(9):1003-11, 2008. <http://www.ncbi.nlm.nih.gov/pubmed/18758303>
105. Salama JK, Stenson KM, List MA, Mell LK, Maccracken E, Cohen EE, Blair E, Vokes EE, Haraf DJ. Characteristics associated with swallowing changes after concurrent chemotherapy and radiotherapy in patients with head and neck cancer. *Arch Otolaryngol Head Neck Surg.* 134(10):1060-5, 2008. <http://archotol.jamanetwork.com/article.aspx?articleid=409360>
106. Cohen EE, Baru J, Huo D, Haraf DJ, Crowley M, Witt ME, Blair EA, Weichselbaum RR, Rosen F, Vokes EE, Stenson K. Efficacy and safety of treating T4 oral cavity tumors with primary chemoradiotherapy. *Head Neck.* 31(8):1013-21, 2009. <http://onlinelibrary.wiley.com/doi/10.1002/hed.21062/abstract>
107. Stenson KM, Kunnavakkam R, Cohen EE, Portugal LD, Blair E, Haraf DJ, Salama J, Vokes EE. Chemoradiation for patients with advanced oral cavity cancer. *Laryngoscope.* 120(1):93-9, 2010. <http://onlinelibrary.wiley.com/doi/10.1002/lary.20716/abstract>
108. Langerman A, Plein C, Vokes EE, Salama JK, Haraf DJ, Blair EA, Stenson KM. Neck response to chemoradiotherapy: complete radiographic response correlates with pathologic complete response in locoregionally advanced head and neck cancer. *Arch Otolaryngol Head Neck Surg.* 135(11):1133-6, 2009. <http://archotol.jamanetwork.com/article.aspx?articleid=410714>
109. Mell LK, Dignam JJ, Salama JK, Cohen EE, Polite BN, Dandekar V, Bhate AD, Witt ME, Haraf DJ, Mittal BB, Vokes EE, Weichselbaum RR. Predictors of competing mortality in advanced head and neck cancer. *J Clin Oncol.* 2010 Jan 1;28(1):15-20. Epub 2009 Nov 23. <http://jco.ascopubs.org/content/28/1/15.long>
110. Pederson AW, Haraf DJ, Witt ME, Stenson KM, Vokes EE, Blair EA, Salama JK. Chemoradiotherapy for locoregionally advanced squamous cell carcinoma of the base of tongue. *Head Neck.* 2010 Nov;32(11):1519-27. <http://onlinelibrary.wiley.com/doi/10.1002/hed.21360/abstract>
111. Pederson AW, Haraf DJ, Blair EA, Stenson KM, Witt ME, Vokes EE, Salama JK. Chemoreirradiation for recurrent salivary gland malignancies. *Radiother Oncol.* 2010 Jun;95(3):308-11. <http://www.sciencedirect.com/science/article/pii/S016781401000157X>
112. Cohen EE, Haraf DJ, Kunnavakkam R, Stenson KM, Blair EA, Brockstein B, Lester EP, Salama JK, Dekker A, Williams R, Witt ME, Grushko TA, Dignam JJ, Lingen MW, Olopade OI, Vokes EE. Epidermal growth factor receptor inhibitor gefitinib added to chemoradiotherapy in locally advanced head and neck cancer. *J Clin Oncol.* 2010 Jul 10;28(20):3336-43. <http://jco.ascopubs.org/content/28/20/3336.long>

113. Choong NW, Mauer AM, Haraf DC, Ferguson MK, Sandler AB, Kesler KA, Fishkin PA, Ansari RH, Wade J 3rd, Krauss SA, Sciortino DF, Posner MC, Kocherginsky M, Hoffman PC, Szeto L, Vokes EE. Long-term outcome of a phase II study of docetaxel-based multimodality chemoradiotherapy for locally advanced carcinoma of the esophagus or gastroesophageal junction. *Med Oncol*. 2011 Dec;28 Suppl 1:S152-61.
<http://link.springer.com/article/10.1007%2Fs12032-010-9658-1>
114. Choe KS, Salama JK, Stenson KM, Blair EA, Witt ME, Cohen EE, Haraf DJ, Vokes EE. Adjuvant chemotherapy prior to postoperative concurrent chemoradiotherapy for locoregionally advanced head and neck cancer. *Radiother Oncol*. 2010 Nov;97(2):318-21.
<http://www.sciencedirect.com/science/article/pii/S0167814010005293>
115. Mouw KW, Haraf DJ, Stenson KM, Cohen EE, Xi X, Witt ME, List M, Blair EA, Vokes EE, Salama JK. Factors associated with long-term speech and swallowing outcomes after chemoradiotherapy for locoregionally advanced head and neck cancer. *Arch Otolaryngol Head Neck Surg*. 2010 Dec;136(12):1226-34.
<http://archotol.jamanetwork.com/article.aspx?articleid=497098>
116. Salama JK, Haraf DJ, Stenson KM, Blair EA, Witt ME, Williams R, Kunnavakkam R, Cohen EE, Seiwert T, Vokes EE. A randomized phase II study of 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy compared with bevacizumab plus 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy for intermediate-stage and T4N0-1 head and neck cancers. *Ann Oncol*. 2011 Oct;22(10):2304-9.
<http://annonc.oxfordjournals.org/content/22/10/2304.long>
117. Villaflor VM, Haraf D, Salama JK, Kocherginsky M, Langerman A, Gomez-Abuin G, Beniwal P, Blair EA, Stenson KM, Portugal L, Seiwert T, Williams RD, Dekker AJ, Witt ME, Vokes EE, Cohen EE. Phase II trial of pemetrexed-based induction chemotherapy followed by concomitant chemoradiotherapy in previously irradiated patients with squamous cell carcinoma of the head and neck. *Ann Oncol*. 2011 Nov;22(11):2501-7.
<http://annonc.oxfordjournals.org/content/22/11/2501.long>
118. Pederson AW, Salama JK, Witt ME, Stenson KM, Blair EA, Vokes EE, Haraf DJ. Concurrent Chemotherapy and Intensity-Modulated Radiotherapy for Organ Preservation of Locoregionally Advanced Oral Cavity Cancer. *Am J Clin Oncol*. 2011 Aug;34(4):356-61.
<http://www.ncbi.nlm.nih.gov/pubmed/21633289>
119. Choe KS, Haraf DJ, Solanki A, Cohen EE, Seiwert TY, Stenson KM, Blair EA, Portugal L, Villaflor VM, Witt ME, Vokes EE, Salama JK. Prior chemoradiotherapy adversely impacts outcomes of recurrent and second primary head and neck cancer treated with concurrent chemotherapy and reirradiation. *Cancer*. 2011 Oct 15;117(20):4671-8.
<http://onlinelibrary.wiley.com/doi/10.1002/cncr.26084/abstract>
120. Shumway D, Corbin K, Salgia R, Hoffman P, Villaflor V, Malik RM, Haraf DJ, Vigneswaren WT, Shaikh AY, Connell PP, Ferguson MK, Salama JK. Pathologic response rates following definitive dose image-guided chemoradiotherapy and resection for locally advanced non-small cell lung cancer. *Lung Cancer*. 2011 Dec;74(3):446-50.
<http://www.sciencedirect.com/science/article/pii/S0169500211002704>
121. Pederson AW, Salama JK, Haraf DJ, Witt ME, Stenson KM, Portugal L, Seiwert T, Villaflor VM, Cohen EE, Vokes EE, Blair EA. Adjuvant

- chemoradiotherapy for locoregionally advanced and high-risk salivary gland malignancies. *Head Neck Oncol.* 2011 Jul 26;3:31.
<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3189162/>
122. Salama JK, Hasselle MD, Chmura SJ, Malik R, Mehta N, Yenice KM, Villaflor VM, Stadler WM, Hoffman PC, Cohen EE, Connell PP, Haraf DJ, Vokes EE, Hellman S, Weichselbaum RR. Stereotactic body radiotherapy for multisite extracranial oligometastases: Final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease. *Cancer.* 2012 Jun 1;118(11):2962-70.
<http://onlinelibrary.wiley.com/doi/10.1002/cncr.26611/abstract>
123. Stenson KM, Maccracken E, Kunnavakkam R, W Cohen EE, Portugal LD, Villaflor V, Seiwert T, Blair E, Haraf DJ, Salama JK, Vokes EE. Chemoradiation for patients with large-volume laryngeal cancers. *Head Neck.* 2012 Aug;34(8):1162-7.
<http://onlinelibrary.wiley.com/doi/10.1002/hed.21888/abstract>
124. Hasselle MD, Haraf DJ, Rusthoven KE, Golden DW, Salgia R, Villaflor VM, Shah N, Hoffman PC, Chmura SJ, Connell PP, Vokes EE, Weichselbaum RR, Salama JK. Hypofractionated Image-Guided Radiation Therapy for Patients with Limited Volume Metastatic Non-small Cell Lung Cancer. *J Thorac Oncol.* 2012 Feb;7(2):376-81.
<http://www.ncbi.nlm.nih.gov/pubmed/22198429>
125. Mouw KW, Solanki AA, Stenson KM, Witt ME, Blair EA, Cohen EE, Vokes EE, List M, Haraf DJ, Salama JK. Performance and quality of life outcomes for T4 laryngeal cancer patients treated with induction chemotherapy followed by chemoradiotherapy. *Oral Oncol.* 2012 Oct;48(10):1025-30.
<http://www.sciencedirect.com/science/article/pii/S1368837512001327>
126. Seiwert TY, Darga T, Haraf D, Blair EA, Stenson K, Cohen EE, Salama JK, Villaflor V, Witt ME, Lingen MW, Weichselbaum RR, Vokes EE. A phase I dose escalation study of Ad GV.EGR.TNF.11D (TNFerade™ Biologic) with concurrent chemoradiotherapy in patients with recurrent head and neck cancer undergoing re-irradiation. *Ann Oncol.* 2013;24(3):769-76.
<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3662388/>
127. Golden DW, Rudra S, Witt ME, Nwizu T, Cohen EE, Blair E, Stenson KM, Vokes EE, Haraf DJ. Outcomes of induction chemotherapy followed by concurrent chemoradiation for nasopharyngeal carcinoma. *Oral Oncol.* 2013 Mar;49(3):277-82.
<http://www.sciencedirect.com/science/article/pii/S1368837512003223>
128. Maggiore RJ, Curran EK, Witt ME, Haraf DJ, Vokes EE, Cohen EE. Survival and selected outcomes of older adults with locally advanced head/neck cancer treated with chemoradiation therapy. *J Geriatr Oncol.* 2013 Oct;4(4):327-33.
<http://www.sciencedirect.com/science/article/pii/S1879406813000507>
129. Zakeri K, MacEwan I, Vazirnia A, Cohen EE, Spiotto MT, Haraf DJ, Vokes EE, Weichselbaum RR, Mell LK. Race and competing mortality in advanced head and neck cancer. *Oral Oncol.* 2014 Jan;50(1):40-4.
<http://www.sciencedirect.com/science/article/pii/S1368837513006957>
130. Rudra S, Spiotto MT, Witt ME, Blair EA, Stenson K, Haraf DJ. Lymph node density--prognostic value in head and neck cancer. *Head Neck.* 2014 Feb;36(2):266-72. <http://onlinelibrary.wiley.com/doi/10.1002/hed.23299/abstract>
131. Cohen EE, Karrison TG, Kocherginsky M, Mueller J, Egan R, Huang CH, Brockstein BE, Agulnik MB, Mittal BB, Yunus F, Samant S, Raez LE, Mehra R, Kumar P, Ondrey F, Marchand P, Braegas B, Seiwert TY, Villaflor VM, Haraf DJ, Vokes EE. Phase III randomized trial of induction chemotherapy in patients with N2

- or N3 locally advanced head and neck cancer. *J Clin Oncol*. 2014 Sep 1;32(25):2735-43. <http://jco.ascopubs.org/content/32/25/2735.long>
132. Das LC, Karrison TG, Witt ME, Muller C, Stenson K, Blair EA, Cohen EE, Seiwert TY, Haraf DJ, Vokes EE. Comparison of outcomes of locoregionally advanced oropharyngeal and non-oropharyngeal squamous cell carcinoma over two decades. *Ann Oncol*. 2015 Jan;26(1):198-205. <http://annonc.oxfordjournals.org/content/26/1/198.long>

(b) Peer-reviewed works in 'non-traditional' outlets:

1. "Up-To-Date," online medical resource. Entries related to Head and Neck Cancer. Wolters Kluwer, Boston, MA. <http://www.uptodate.com/contents/search>

(c) Peer-reviewed works accepted or in press

(d) Non-peer-reviewed original articles

1. Haraf DJ, Weichselbaum RR: Treatment selection in T1 and T2 vocal cord carcinoma. *Oncology* 2:41-47, 1988. <http://www.ncbi.nlm.nih.gov/pubmed/3275034>
2. Springate C, Haraf DJ, Weichselbaum RR: Temporal bone chemodectomas: Comparing surgery and radiation therapy. *Oncology* 5:131-137, 1991. <http://www.ncbi.nlm.nih.gov/pubmed/1651096>
3. Haraf DJ, Brachman DG, Fleming G: The expanding role of chemotherapy and radiation in colorectal and anal carcinoma. *J Infusional Chemotherapy*. 2:36-44, 1992.
4. Vokes EE, Haraf DJ, Panje WR, Schilsky RL, Weichselbaum RR: Hydroxyurea with concomitant radiotherapy for locally advanced head and neck cancer. *Semin Oncol*. 19(suppl 9), 53-58, 1992. <http://www.ncbi.nlm.nih.gov/pubmed/1641658>
5. Haraf DJ, Devine D, Ihde D, Vokes EE: The evolving role of systemic therapy in carcinoma of the lung. *Semin Oncol*. 19(suppl 11):72-87, 1992. <http://www.ncbi.nlm.nih.gov/pubmed/1324527>
6. Vokes EE, Haraf DJ, Weichselbaum RR, McEvelly JM, Sutton HG, Panje WR: Perspectives on combination chemotherapy with concomitant radiotherapy for poor prognosis head and neck cancer. *Semin Oncol*. 19(suppl 11):47-56, 1992. <http://www.ncbi.nlm.nih.gov/pubmed/1509281>
7. Sweeney PJ, Haraf DJ, Vokes EE, Dougherty M, Weichselbaum RR: Radiation therapy in head and neck cancer: Indications and limitations. *Semin Oncol* 21:296-303, 1994. <http://www.ncbi.nlm.nih.gov/pubmed/8209262>
8. Wong WW, Haraf DJ, Weichselbaum RR, Mick R, Vokes EE: Response to editorial by Harari and Fowler. *Int J Radiat Oncol Biol Phys*. 29:216, 1994. <http://www.sciencedirect.com.proxy.uchicago.edu/science/article/pii/0360301694902534>
9. Vokes EE, Drinkard LC, Samuels BL, Hoffman PC, Watson S, Bitran JD, Haraf DJ, Ferguson MF, Golomb HM: A phase II study of cisplatin, fluorouracil and leucovorin augmented by navelbine for advanced non-small cell lung cancer: Rational and study design. *Semin Oncol* 21(5 suppl 10):79-83; discussion 83-84, 1994. <http://www.ncbi.nlm.nih.gov/pubmed/7973772>
10. Weichselbaum RR, Beckett MA, Vokes EE, Brachman DG, Haraf D, Hallahan D, Kufe D. Cellular and molecular mechanisms of radioresistance. *Cancer*

- Treat Res. 1995;74:131-40.
<http://www.ncbi.nlm.nih.gov/pubmed/7779612>
11. Vokes EE, Stupp R, Haraf DJ, Moran W, Malone D, Wenig B, Sweeney P, Weichselbaum RR: Hydroxyurea with continuous infusion paclitaxel, 5-FU, and concomitant radiotherapy for poor prognosis head and neck cancer. *Semin Oncol* 22(3):47-52, 1995.
<http://www.ncbi.nlm.nih.gov/pubmed/7597433>
 12. Haraf DJ, Weichselbaum RR, Vokes EE. Timing and sequencing of chemoradiotherapy. *Cancer Treat Res.* 1995;74:173-98.
<http://www.ncbi.nlm.nih.gov/pubmed/7779616>
 13. Vokes EE, Haraf DJ, Stenson K, Stupp R, Malone D, Levin J, Weichselbaum RR: The role of paclitaxel in the treatment of head and neck cancer. *Semin Oncol* 22(5):8-12, 1995. <http://www.ncbi.nlm.nih.gov/pubmed/7481866>
 14. Vokes EE, Haraf DJ, Masters GA, Hoffman PC, Drinkard LC, Ferguson M, Olak J, Watson S, Golomb HM. Vinorelbine (Navelbine), cisplatin, and concomitant radiation therapy for advanced malignancies of the chest: a Phase I study. *Semin Oncol.* 1996 Apr;23(2 Suppl 5):48-52.
<http://www.ncbi.nlm.nih.gov/pubmed/8610237>
 15. Haraf DJ, Weichselbaum: In Response to Drs. Hanks and Lee. *Int J Radiat Oncol Biol Phys* 34:757, 1996.
<http://www.sciencedirect.com.proxy.uchicago.edu/science/article/pii/0360301696900905>
 16. . Haraf DJ, Stenson K, List M, Witt ME, Weichselbaum RR, Vokes EE: Continuous infusion paclitaxel, 5-fluorouracil with hydroxyurea and concomitant radiotherapy in patients with advanced or recurrent head and neck cancer. *Semin Oncol* 24(suppl 2):68-71, 1997.
<http://www.ncbi.nlm.nih.gov/pubmed/9045341>
 17. Vokes EE, Masters GA, Mauer AM, Haraf DJ, Hoffamn PC, Golomb HM: Clinical studies of Docetaxel (Taxotere) and concomitant chest therapy. *Semin Oncol* 24(4 suppl 14):S14-26-S14-29, 1997.
<http://www.ncbi.nlm.nih.gov/pubmed/9335521>
 18. Vokes EE, Mauer AM, Hoffman PC, Haraf DJ: Combined modality therapy in non-small cell lung and esophageal cancer: a phase I dose-escalation study of docetaxel with concurrent radiotherapy. *Semin Oncol* 25(3 Suppl 8):28-32, 1998. <http://www.ncbi.nlm.nih.gov/pubmed/9704674>
 19. Vokes EE, Brockstein BE, Humerickhouse R, Haraf DJ: Oral 5-FU alternatives for the treatment of head and neck cancer. *Oncology* 12(10 Suppl 7):35-8, 1998. <http://www.cancernetwork.com/oncology-journal/oral-5-fu-alternatives-treatment-head-and-neck-cancer>
 20. Vokes EE, Haraf DJ, Brockstein BE, Weichselbaum RR: Paclitaxel, 5-fluorouracil, hydroxyurea, and concomitant radiation therapy for poor-prognosis head and neck cancer. *Semin Radiat Oncol* 9(2 suppl 1):70-76, 1999.
<http://www.ncbi.nlm.nih.gov/pubmed/10210543>
 21. Vokes EE, Haraf DJ, Kies MS: The use of concurrent chemotherapy and radiotherapy for locoregionally advanced head and neck cancer. *Semin Oncol* 27(4 suppl 8):34-38, 2000.
<http://www.ncbi.nlm.nih.gov/pubmed/10952436>
 22. Garofallo M, Haraf DJ: Reirradiation: a potentially curative approach to locally or regionally recurrent head and neck cancer. *Curr Opin Oncol* 14:330-333, 2002. <http://www.ncbi.nlm.nih.gov/pubmed/11981280>
 23. Kao J, Garofalo MC, Milano MT, Chmura SJ, Citron JR, Haraf DJ: Reirradiation of recurrent and second primary head and neck malignancies: a

- comprehensive review. *Cancer Treat Rev* 29:21-30, 2003.
<http://www.sciencedirect.com/science/article/pii/S0305737202000968>
24. Mantz CA, Vokes EE, Kies M, Mittal B, Witt ME, List MA, Weichselbaum RR, Haraf DJ: Intensive induction chemotherapy followed by concomitant chemoradiotherapy in the management of locoregionally advanced carcinoma of the pyriform sinus. *Recent Advances and Research Updates* 4:113-123, 2003.
www.australasiancancer.org/journal/_download-article.php?id=429
 25. Mittal BB, Pauloski BR, Haraf DJ, Pelzer HJ, Argiris A, Vokes EE, Rademaker A, Logemann JA: Swallowing dysfunction- preventative and rehabilitation strategies in patients with head-and-neck cancers treated with surgery, radiotherapy, and chemotherapy: A critical review. *Int J Radiat Oncol Biol Phys* 57:1219-1230, 2003.
<http://www.sciencedirect.com/science/article/pii/S0360301603014548>
 26. Argiris A, Haraf DJ, Kies MS, Vokes EE: Intensive concurrent chemoradiotherapy for head and neck cancer with 5-fluorouracil and hydroxyurea based regimens: Reversing a pattern of failure. *Oncologist* 8:350-360, 2003.
<http://theoncologist.alphamedpress.org/content/8/4/350.long>
 27. Kao J, Garofalo MC, Milano MT, Chmura SJ, Citron JR, Haraf DJ. Reirradiation of recurrent and second primary head and neck malignancies: a comprehensive review. *Cancer Treat Rev.* 2003 Feb;29(1):21-30.
<http://www.sciencedirect.com/science/article/pii/S0305737202000968>
 28. Chmura SJ, Milano MT, Haraf DJ. Reirradiation of recurrent head and neck cancers with curative intent. *Semin Oncol* 31:816-21, 2004.
<http://www.sciencedirect.com/science/article/pii/S0093775404004002>
 29. Cohen EE, Kocherginsky M, Karrison T, Seiwert TY, Haraf DJ, Brockstein B, Vokes EE. Reply to S. Chakraborty et al. *J Clin Oncol.* 2015 Feb 9. pii: JCO.2014.59.6189.
<http://jco.ascopubs.org/content/early/2015/02/03/JCO.2014.59.6189.long>

(e) Books:

(f) Book chapters:

1. Vokes EE, Haraf DJ, Panje WR, McEvelly JM, Kozloff MF, Goldman D, Clendenin N, Tybor AG, Collier M, Weichselbaum RR. 1991. Cisplatin, 5-fluorouracil and high dose oral leucovorin (PFL) with methotrexate and piritrexim as neoadjuvant chemotherapy for head and neck cancer. In: Banzet P, Holland JF, Khayat D, Weil M. 1991. *Proceedings of the 3rd International Congress on Neo-Adjuvant Chemotherapy.* pp 58-60. Springer-Verlag, Paris.
2. Haraf DJ, Vokes EE, Panje WR, Weichselbaum RR. 1991. Efficacy of concomitant chemoradiotherapy in poor prognosis head and neck cancer. In: Banzet P, Holland JF, Khayat D, Weil M. 1991. *Proceedings of the 3rd International Congress on Neo-Adjuvant Chemotherapy.* pp 61-65. Springer-Verlag, Paris.
3. Vokes EE, Haraf DJ, Weichselbaum RR, Brachman D. 1993. Induction chemotherapy; promises and limitations. In: Johnson JT, Didolkar MS. 1993. *Head and Neck Cancer, Volume III. Proceedings of the third international conference on head and neck cancer, San Francisco, July 26-30, 1992.* p 321-326. Excerpta Medica, Amsterdam.

4. Weichselbaum RR, Beckett MA, Vokes EE, Hallahan DE, Haraf DJ, Brachman DG. 1993. Cellular and molecular basis for radioresistance in head and neck cancer. In: Johnson JT, Didolkar MS. 1993. Head and Neck Cancer, Volume III. Proceedings of the third international conference on head and neck cancer, San Francisco, July 26-30, 1992. p 399-407. Excerpta Medica, Amsterdam.
5. Brachman DG, Haraf DJ, Weichselbaum RR. 1994. Radiation therapy of colorectal and anal carcinoma. In: Block GE, and Moosa AR. 1994. Operative Colorectal Surgery. p 268-284. W.B. Saunders, Philadelphia, PA.
6. Kies MS, Haraf DJ, Mittal B, Athanasiadis I, Kozloff M, McEvelly J, Mick R, Moran W, Panje W, Pelzer H, Sheehan TD, Weichselbaum R, Wenig B, Vokes EE. 1994. A phase II trial of induction cisplatin, 5-FU leucovorin, and interferon a-2B (PFL-a) followed by concurrent hydroxyurea, 5-FU and radiation for stage IV squamous cell cancers of the head and neck (HNC). In: Banzet, Holland, Khayat & Weil. 1994. Cancer Treatment: An Update. pp 207-210. Springer-Verlag, Paris.
7. Vokes EE, Haraf DJ, Moran W, Wenig B, Brachman D, Rubin S, McEvelly JM, Lockett P, Panje WR, Weichselbaum RR. 1994. Intensified concomitant chemoradiotherapy for poor prognosis head and neck cancer. In: Banzet, Holland, Khayat & Weil. 1994. Cancer Treatment: An Update. pp 283-287. Springer-Verlag, Paris.
8. Haraf DJ, Vokes EE. 1995. Timing and sequencing of chemoradiotherapy. In: Hong and Weber. 1995. Head and Neck Oncology 4. pp 173-197. Kluwer Academic Publishers, Boston, MA.
9. Weichselbaum RR, Beckett MA, Vokes EE, Hallahan DE, Haraf DJ, Brachman DG. 1995. Cellular and molecular mechanisms for radioresistance in head and neck cancer. In: Hong and Weber. 1995. Head and Neck Oncology 4. pp 131-140. Kluwer Academic Publishers, Boston, MA.
10. Sweeney PJ, Haraf DJ, Vokes EE, Moran W, Weichselbaum RR. 1996. T3 lesion of the larynx. In: Winchester DP, Brennan MF, Dodd GD Jr, Henson DE, Kennedy BJ, Steele GD Jr, Wilson JF. 1996. Tumor Board Case Management. pp 27-31. Lippincott-Raven, Philadelphia.
11. Lee MM, Haraf DJ, Weichselbaum RR. 1996. Management of the clinically negative neck. In: Shah JP and Johnson JT. 1996. Proceedings of the 4th International Conference on Head and Neck Cancer 1996 July 28 to August 1, Toronto, ON, Canada, 116 Arlington, VA. pp 564-570. The Society of Head and Neck Surgeons and American Society of Head and Neck Surgery.

(g) Other works that are publically available (websites, interviews, publications in the popular press, testimony, computer programs, protocols, reagents, inventions, patents not listed above, etc.)

(g) Clinical trials that are ongoing and unpublished

1. Investigation of HPV status in locally recurrent oropharynx head and neck tumors (IRB 12-2127). Role: PI. Status: open to accrual.
2. IRB 121554: Nab-Paclitaxel-based re-induction chemotherapy followed by response-stratified chemoradiotherapy in patients with previously treated squamous cell carcinoma of the head and neck.

3. Long Term Database Collection for Head and Neck Cancer (IRB 13-1111). Role: PI. Status: open to accrual.
4. An exploratory pilot study of Nab-paclitaxel based induction chemotherapy followed by response-stratified locoregional therapy for patients with stage III and IV HPV-related Oropharyngeal Cancer - the OPTIMA HPV Trial. OPTIMA = OroPharyngeal Tumor Induction chemotherapy and response-stratified locoregional therapy trial in order to Minimize long term Adverse events (IRB 14-0639). Role: PI. Status: open to accrual.

(i) Works in review, in preparation, etc. not yet publically available [list ONLY if available for BSD review]

FUNDING

(a) Past:

1. Gerald Norton Memorial Corporation. Total award: \$25,000 annual gift. Project period: 1990-1999.
2. American Cancer Society. PI: Haraf. Title: "Clinical Oncology Career Development Award." Total direct costs: \$30,000. Annual salary recovery or effort: 10%. Project period: 1991-1994.
3. Velda & Robert Svendsen Foundation. Total award: \$50,000 gift. Project period: 1994.
4. Schereville Central Lions Club. Total award: \$600 gift. Project period: 1994.
5. Velda & Robert Svendsen Foundation. Total award: \$25,000 annual gift. Project period: 1996-2000.
6. CA14599-27. PI: Haraf. Title: "University of Chicago Cancer Research Center." Total direct costs: \$50,000. Annual salary recovery or effort: 15%. Project period: 1998-2003.
7. CA 11921-03. PI: Haraf. Title: "Oral Cancer Center Grant." Total direct costs: \$50,000. Annual salary recovery or effort: 5%. Project period: 1998-2001.
8. Gerald Norton Memorial Corporation. Total award: \$15,000 gift. Project period: 2000.
9. Gerald Norton Memorial Corporation. Total award: \$10,000 gift. Project period: 2001.
10. Velda & Robert Svendsen Foundation. Total award: \$25,000 annual gift. Project period: 2001-2015.
11. Elizabeth Lanzl. Total award: \$5,000 gift. Project period: 2006.
12. NIH R01 DC007659. PI: Logemann. My role: Site-PI. Title: "Oral Function After IMRT." Annual salary recovery or effort: 4%. Project period: 2006-2010.

(b) Current:

(c) Pending:

HONORS, PRIZES, AND AWARDS

- | | |
|-----------|--|
| 1973-1976 | Dean's List, Northern Illinois University |
| 1976: | Graduated Summa Cum Laude, Northern Illinois University |
| 1976-1978 | University Research Fellow, University of Health Sciences/The Chicago Medical School |
| 1977-1978 | Sprague Foundation Fellow, University of Health Sciences/The Chicago Medical School |

1982	Scholastic Achievement Award, University of Health Sciences/The Chicago Medical School
1987-1988	Chief Resident, Michael Reese/University of Chicago, Department of Radiation and Cellular Oncology
1999	Selected for Castle Connolly "Top Doctors: Chicago Metro Area" First Edition
2001	Selected for Castle Connolly "Top Doctors: Chicago Metro Area" Second Edition
2002	Selected for Castle Connolly "Top Doctors: Chicago Metro Area" Third Edition
2003	International Research Promotion Council, "Eminent Scientist of the Year."
2004	Samuel Hellman "Teacher of the Year" award
2005	Selected for Castle Connolly "America's Top Doctors for Cancer 2005."
2006-2014	Selected for Chicago Magazine Top Doctor.
2006-2014	Selected for Castle Connolly "America's Top Doctors for Cancer."
2006-2014	Selected for Castle Connolly "America's Top Doctors"
2007-2014	Selected for "Best Doctors in America" database.
2012	Samuel Hellman "Teacher of the Year" award
2012	Buchsbaum Institute Senior Faculty Scholar

INVITED SPEAKING

1990	Cisplatin (CDDP), 5-fluorouracil (5-FU), and hydroxyurea (HU) with concomitant radiotherapy (RT) for advanced solid tumors. 3 rd International Conference on the Interaction of Radiation Therapy and Systemic Therapy, Monterey, CA.
1990	Neoadjuvant chemotherapy (NCT) followed by surgery (S) and concomitant chemoradiotherapy (CXRT) for locally advanced head and neck cancer (HNC). 3 rd International Conference on the Interaction of Radiation Therapy and Systemic Therapy, Monterey, CA.
1991	Update of radiotherapeutic techniques and dental management. The Third National Conference of Special Care Issues in Dentistry. Chicago, IL.
1991	Management of tumors of the ear and temporal bone. 77th Clinical Congress of the American College of Surgeons. Chicago, IL.
1991	Efficacy of concomitant chemoradiotherapy in poor prognosis head and neck cancer. The 3 rd International Congress on Neo-Adjuvant Chemotherapy. Paris, France.
1991	Interferon-alpha-2b (INF) as a modulator of PFL induction chemotherapy for stage IV head and neck cancer. European Conference of Clinical Oncology.
1994	Session chair: Fourth Research Workshop on the Biology, Prevention, and Treatment of Head and Neck Cancer. Sept 8-11, 1994, Arlington, VA.
1994	Radiation therapy in head and neck cancer: A proven standard with new horizons. 10 th Workshop in Head and Neck Surgery. Chicago, IL.
1996	Results of reirradiation & concomitant chemotherapy in recurrent unresectable head and neck cancer (HNC). 4 th International Conference on Head and Neck Cancer.
1999	The role of reirradiation in previously irradiated locally recurrent head and neck cancer. 1 st International Conference on Malignancies of the Chest and Head and Neck. Chicago, IL.

- 2000 Reirradiation of locally recurrent head and neck cancer. 5th International Conference on Head and Neck Cancer. San Francisco, CA.
- 2000 Reirradiation of as a treatment option for recurrent head and neck cancer. Meeting of the Chicago Area Radiation Therapists. Chicago, IL.
- 2001 The emerging role to IMRT in radiation treatment. Meeting of the American Association of Medical Dosimetrists. Lisle, IL.
- 2002 Recurrent head and neck cancer: Palliative options. ASCO Annual Meeting. Orlando, FL.

INVITED, ELECTED, OR APPOINTED EXTRAMURAL SERVICE

- 1999 Member of the Program Committee: 1st International Conference on Malignancies of the Chest and Head and Neck. Chicago, IL.
- 2001 Member of the Program Committee: 2nd International Conference on Malignancies of the Chest and Head and Neck. Chicago, IL.

Reviewer for The Journal of Clinical Oncology.
 Reviewer for Cancer.
 Reviewer for Cancer Research.
 Reviewer for Head and Neck.
 Reviewer for The Cancer Journal.
 Reviewer for International Journal of Radiation Oncology, Biology, Physics.
 Reviewer for Lancet Medicine.

PROFESSIONAL SOCIETIES

Elected or invited membership:

Phi Kappa Phi Honor Society
 Omicron Delta Kappa Honor Society
 Phi Sigma Biological Honor Society
 Dormitory Council President, 1976, Northern Illinois University
 Graduate Student Association, Vice President, 1977, UHS/CMS
 Alpha Omega Alpha Honor Medical Society, Vice President 1982, UHS/CMS

Other:

American College of Physicians
 American Society of Therapeutic Radiology
 American College of Radiation Oncology

EDUCATION

The College (B.A., B.S.):

Graduate programs (Ph.D.):

Pritzker School of Medicine (M.D.):

Graduate medical education (residency and clinical fellowships):

1988- Instructor, Department of Radiation and Cellular Oncology, Radiobiology Course

CLINICAL

1988- Head and Neck Oncology Conference (weekly)
1988-1993 Chest Oncology Conference (weekly)
1989- Preceptor, Radiation Oncology Residents
1991-1996 Genito-urinary Oncology Conference (bi-weekly)
1991- Preceptor, Radiation Oncology, medical student elective
1993-1994 Gynecologic Oncology Conference (weekly)
1994- Chest Oncology Conference (weekly)
1995- Preceptor, Dental Fellow Radiation Oncology Rotation

SERVICE

University of Chicago

Committee membership:

1988- Department of Radiation and Cellular Oncology, Head and Neck Cancer Committee
1988- Department of Radiation and Cellular Oncology, Lung Cancer Committee
1988-2007 Department of Radiation and Cellular Oncology, Prostate Cancer Committee
1991 Housestaff Review Committee
1992- Faculty Advisory Committee
1993- Medical Liability Committee
1996 Housestaff Review Committee
1998 Tumor Registry Cancer Committee
2002 AIMS Committee
2004- COAP

Leadership:

1991-2007 Chairman, Department of Radiation and Cellular Oncology Quality Assurance Committee
1991- Chairman, Department of Radiation and Cellular Oncology Clinical Trials Committee
1993-1994 Vice-Chairman, UCCRC Clinical Trials Review Committee
1994-2003 Chairman, UCCRC Clinical Trials Review Committee
2006- Ambulatory Operations Director for Radiation Oncology
2012- Ambulatory Operations Committee Medical Director for Radiation Oncology

Other:

1994 Transportation Users Group
1994 Ambulatory Care Advisory Council
1999 Physician's Fund Raising Working Group

Extramural (not indicated above)

Leadership roles:

Other: